Apollo Endosurgery

What Apollo Endosurgery does

Apollo Endosurgery, Inc. was a publicly traded medical device company headquartered in Austin, Texas, founded in 2006 and operating under NASDAQ: APEN prior to its acquisition by Boston Scientific Corporation in April 2023 for $615 million. The company developed minimally invasive endoscopic devices for gastrointestinal weight-loss procedures, with two core platforms: the OverStitch Endoscopic Suturing System (including the next-generation OverStitch NXT) that enables full-thickness internal suturing through the mouth without incisions, supporting Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe) procedures; and the ORBERA Intragastric Balloon System, a temporary balloon implant placed for up to six months to create satiety. Indicated for adult patients with obesity (BMI 30-50 for OverStitch/ESG; 30-40 for Orbera), the products address patients who failed supervised weight-control programs or who regained weight after gastric bypass. Regulatory positioning was anchored by FDA de novo clearances for endoscopic bariatric systems, establishing first-in-class authorization for the incisionless approach.

The company sold capital equipment (OverStitch) and disposable/implantable components (Orbera, suturing reloads) to hospitals, ambulatory surgical centers, and specialty clinics through an enterprise field sales motion targeting gastroenterologists and bariatric surgeons. Revenue was therefore hardware-led with consumable-driven recurring use per procedure, supplemented by patient demand generation via the Find a Doctor locator and education resources now housed under Boston Scientific's Endura Weight Loss Solutions brand. Distribution historically relied on Apollo's direct sales force; the April 2023 Boston Scientific acquisition extended reach through BSX's global enterprise network and integrated the Apollo portfolio into BSX's endoluminal surgery franchise, alongside complementary diagnostics such as the 2016 LPATH acquisition and prior capital raises totaling over $300M of equity and debt from investors including Innovatus Capital Partners, PTV Healthcare Capital, H.I.G. Capital, and Novo Holdings.

Name

Apollo Endosurgery

Legal name

Apollo Endosurgery, Inc.

Website

https://apolloendo.com

Company type

Private

Founded year

2006

Operating status

Acquired

Headcount range

101–250 employees

Short description

Apollo Endosurgery, Inc. is an Austin-based medical device company developing minimally invasive endoscopic systems - OverStitch (suturing) and Orbera (intragastric balloon) - that enable incisionless weight-loss procedures (ESG, TORe) for adult patients with obesity, distributed to hospitals and specialty clinics and now operating within Boston Scientific's Endura brand.

Ownership category

akta.pro rank

Product category

Endoscopic Bariatric Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB)

akta.pro secondary industries

Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Advanced Endoscopy (ERCP/EUS/Interventional) (HLAKAEAC)

Keywords

• Endoscopic medical devices
• Bariatric weight loss
• Intragastric balloon systems
• Endoscopic suturing devices
• Minimally invasive surgery

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales: Apollo Endosurgery generated revenue through sale of endoscopic medical devices including the OverStitch suturing system and Orbera intragastric balloon. OverStitch is a capital/reusable device system while Orbera is a temporary implant with a 6-month placement limit. Revenue derived from hospital and specialty clinic purchases.
2. Endoscopic Procedure Products: Revenue from disposable and implantable components used in ESG and TORe procedures. The company provided the full ecosystem of devices needed for endoscopic weight loss procedures.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Apollo Endosurgery develops and manufactures endoscopic medical devices for minimally invasive weight loss procedures. Its core products include the OverStitch Endoscopic Suturing System (used for Endoscopic Sleeve Gastroplasty and Transoral Outlet Reduction procedures) and the ORBERA Intragastric Balloon System. These devices enable gastroenterologists and bariatric surgeons to perform non-surgical bariatric interventions through the mouth, reducing stomach capacity without external incisions.

Product overview

Apollo Endosurgery, acquired by Boston Scientific in 2024, offers a portfolio of minimally invasive endoscopic bariatric and weight management solutions. The core products include the OverStitch™ Endoscopic Suturing System and OverStitch NXT for performing procedures like Endoscopic Sleeve Gastroplasty (ESG) and Transoral Outlet Reduction (TORe), as well as the ORBERA™ Intragastric Balloon System. These products work together as non-surgical weight loss options performed endoscopically through the mouth, designed to reduce stomach capacity and support healthy lifestyle changes.

Differentiator

Problem solved

Functional benefit

Brands

• OverStitch Endoscopic Suturing System: Endoscopic suturing system for bariatric surgery procedures including ESG and TORe
• ORBERA Intragastric Balloon System
• Endura Weight Loss Solutions

Products and services

• OverStitch Endoscopic Suturing System An endoscopic suturing system for bariatric surgery that reduces stomach size by stitching the inside, indicated for adult patients with obesity (BMI 30-50 kg/m2). Sold to healthcare institutions and specialist physicians.
• OverStitch NXT Endoscopic Suturing System The next-generation version of the OverStitch endoscopic suturing system for bariatric and metabolic procedures, designed for use by trained gastroenterologists and bariatric surgeons in healthcare institutions.
• ORBERA Intragastric Balloon System A temporary intragastric balloon system for weight loss therapy, intended for obese adult patients (BMI 30-40 kg/m2) who have failed to achieve weight loss with supervised programs. Maximum placement time is 6 months. Sold to healthcare institutions.
• Endoscopic Sleeve Gastroplasty (ESG) Procedure A one-time endoscopic procedure that uses internal sutures to reduce stomach capacity by 70-80%, performed using the OverStitch system. Indicated for adult patients with obesity (BMI 30-50 kg/m2).
• Transoral Outlet Reduction (TORe) Procedure A procedure performed using the OverStitch system that retightens the connection between the stomach and small intestine for previous gastric bypass patients who have regained weight, restoring portion control.

Quantifiable outcome

• Patients achieve average 13.6% total body weight loss at year one with ESG procedure combined with diet and exercise counseling

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Boston ScientificcoreOEM/ Whitelabel/ Licensing Partner · 1 April 2023Boston Scientific acquired Apollo Endosurgery for $615 million in April 2023 to strengthen its endoluminal surgery offerings. Apollo Endosurgery became a wholly-owned subsidiary of Boston Scientific. The acquisition provided Boston Scientific with Apollo's portfolio of endoscopic suturing systems (OverStitch) and intragastric balloons (Orbera), and access to Apollo's FDA de novo clearances for endoscopic bariatric systems.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Medtronic: Medtronic is listed alongside Apollo as a key player in automated suturing devices, with a broad surgical portfolio and significant R&D and sales reach to compete in endoscopic bariatric tools.
• Smith & Nephew: Smith & Nephew is listed as a key player in automated suturing devices, with a broader wound closure and sports medicine surgical device portfolio competing in the same OR channel.
• B. Braun: B. Braun is identified as a key competitor in automated suturing devices, with hospital-wide medical device and suture portfolios that overlap with Apollo's target customer base.
• Ethicon (Johnson & Johnson): Ethicon is the dominant surgical suturing franchise inside J&J MedTech and overlaps directly with OverStitch as a broad incumbent in automated and endoscopic suturing.
• Becton, Dickinson and Company (BD): BD is called out among key players in automated suturing, with the Bard hernia and biosurgery franchise; comparable as a broad hospital-channel incumbent competing for the same procedural suturing accounts.

Direct peers

• ReShape Lifesciences: ReShape markets the ReShape and Obalon intragastric balloons and merged with Obalon Therapeutics, making it a directly comparable gastric balloon competitor in the same patient segment.
• Spatz FGIA: Spatz FGIA sells the Spatz3 adjustable intragastric balloon, an FDA-cleared direct rival to Apollo's Orbera in the temporary endoscopic weight loss balloon market.
• Allurion Technologies: Allurion develops the swallowable, balloon-free Elipse gastric balloon for endoscopic weight loss—the most direct head-to-head competitor to Apollo's Orbera intragastric balloon in the non-surgical obesity category.

Emerging players

• USGI Medical: USGI Medical develops incisionless endoscopic suturing and tissue approximation tools (e.g., g-Cath EZ, Incisionless Operating Platform) that overlap with Apollo's OverStitch suturing capabilities in advanced GI procedures.

Others

• Boston Scientific Corporation: Boston Scientific acquired Apollo in 2023 for $615M and now owns and distributes the entire portfolio under the Endura brand—relevant as the parent that controls future commercial and R&D direction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Apollo_Endo
• LinkedInlinkedin.com/company/apollo-endosurgery

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds13 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apollo Endosurgery